Colorectal cancer is a leading cause of cancerrelated deaths. Mutations in the innate immune sensor AIM2 are frequently identified in patients with colorectal cancer, but how AIM2 modulates colonic tumorigenesis is unknown. Here, we found that Aim2-deficient mice were hypersusceptible to colonic tumor development. Production of inflammasome-associated cytokines and other inflammatory mediators was largely intact in Aim2-deficient mice; however, intestinal stem cells were prone to uncontrolled proliferation. Aberrant Wnt signaling expanded a population of tumor-initiating stem cells in the absence of AIM2. Susceptibility of Aim2-deficient mice to colorectal tumorigenesis was enhanced by a dysbiotic gut microbiota, which was reduced by reciprocal exchange of gut microbiota with healthy wild-type mice. These findings uncover a synergy between a specific host genetic factor and gut microbiota in determining the susceptibility to colorectal cancer. Therapeutic modulation of AIM2 expression and microbiota has the potential to prevent colorectal cancer.
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In Brief
The cytosolic DNA sensor AIM2 regulates stem cell proliferation in the intestinal mucosa in an inflammasomeindependent fashion, contributing to a decrease in the likelihood of colorectal cancer development.
INTRODUCTION
Colorectal cancer is a leading cause of cancer-related deaths, with 160,000 cases being diagnosed annually in the USA (Markowitz and Bertagnolli, 2009) . Mutations in the gene encoding AIM2 are frequently identified in patients with colorectal cancer. A previous study has shown that more than 50% of tumors from patients with small bowel cancer have frameshift mutations in the gene encoding AIM2 (Schulmann et al., 2005) . Further genetic evidence has shown that frameshift and missense mutations are targeted to the coding regions of the gene encoding AIM2 in colon cancer tissues and cell lines (Kim et al., 2013; Woerner et al., 2007) . These include frameshift mutations in the A10 repeat of exon 6, a deletion mutation in the A6 repeat of exon 5, and a nonsynonymous nucleotide exchange within exon 2 of the gene encoding AIM2-all of which were identified in tumor tissues of patients with colorectal cancer with a high level of microsatellite instability associated with deficiency in mismatch repair (Woerner et al., 2007) . Analysis of 414 colorectal tumors and matching control tissues further revealed that 67% of the tumors displayed reduced expression of the gene encoding AIM2 relative to control tissues (Dihlmann et al., 2014) . Nearly 50% of patients who completely lacked expression of the gene encoding AIM2 in their tumor cells die from their cancer within 5 years of diagnosis, whereas over 70% of patients whose tumor cells retained some expression survived beyond 5 years after their diagnosis (Dihlmann et al., 2014) . A better understanding of the biological function of AIM2 in colorectal cancer is key to identifying therapies that could be used in the treatment of this disease.
AIM2 is a cytosolic double-stranded DNA (dsDNA) receptor that contributes to the host defense against bacterial and viral pathogens, such as Francisella tularensis and vaccinia virus, respectively (Bü rckstü mmer et al., 2009; Fernandes-Alnemri et al., 2009; Fernandes-Alnemri et al., 2010; Hornung et al., 2009; Rathinam et al., 2010; Roberts et al., 2009 ). We previously identified that infection by the cytosolic bacterium Francisella tularensis subspecies novicida activates the transcription factor IRF1, which induces production of interferon-inducible GTPases called guanylate-binding proteins . Guanylatebinding proteins attack and kill bacteria in the cytoplasm, resulting in the liberation of bacterial DNA for recognition by AIM2 Meunier et al., 2015) . Upon binding of dsDNA in the cytoplasm of infected cells, AIM2 recruits the adaptor protein ASC to assemble an inflammasome complex that activates caspase-1, a cysteine protease that induces pyroptosis and mediates the cleavage of the inflammatory cytokines IL-1b and (E and F) Number and size of colon tumors in WT (n = 34) and Aim2 -/-(n = 27) mice.
(G) Body weight change of mice pooled from six independent experiments.
(legend continued on next page) IL-18. Structural analysis of AIM2 revealed that the HIN200 domain binds dsDNA, whereas the pyrin domain recruits ASC (Jin et al., 2012) . DNA accumulated in keratinocytes also activates the AIM2 inflammasome to drive the release of IL-1b in lesions of patients with psoriasis (Dombrowski et al., 2011) , suggesting that AIM2 has the capacity to recognize damage-associated molecular patterns released by the cell. Activation of AIM2 must, therefore, be tightly regulated to allow clearance of pathogens while maintaining homeostasis to prevent the development of autoimmune conditions. In this study, we found that AIM2-deficient (Aim2 -/-) mice developed more tumors in the colon following azoxymethane (AOM)-and dextran sulfate sodium (DSS)-induced colitis-associated tumorigenesis. Unlike its role in the host defense against infection, AIM2 protected against tumorigenesis by controlling intestinal epithelial cell proliferation via a mechanism independent of inflammasomes and inflammatory mediators. Upon dysregulated Wnt signaling, AIM2 suppressed expansion of tumor-initiating intestinal stem cells lining the base of the crypt. Remarkably, reciprocal exchange of the gut microbiota between healthy WT mice and Aim2 -/-mice reduced the susceptibility of Aim2 -/-mice to colorectal tumorigenesis. These findings revealed a role for AIM2 and its synergy with gut microbiota in the development of colorectal cancer.
RESULTS
The DNA Receptor AIM2 Is Required to Prevent Colorectal Cancer Mutations in the gene encoding AIM2 are associated with colorectal cancer, and reduced expression of this gene is linked to increased mortality in humans (Dihlmann et al., 2014; Kim et al., 2013; Schulmann et al., 2005; Woerner et al., 2007) . In mice, the gene encoding AIM2 was widely expressed in the intestine, especially in the colon ( Figure 1A ), which suggested a role for AIM2 in regulating homeostasis in the gastrointestinal tract. To investigate the role of AIM2 in colorectal cancer, we used an established model of colitis-associated colorectal tumorigenesis whereby mice were injected intraperitoneally with AOM, followed by three rounds of DSS treatment (Figure S1A) . Expression of the gene encoding AIM2 was drastically reduced in the colon of WT mice 14 or 80 days after injection of AOM ( Figures 1B and 1C ). Reduced expression of the gene encoding AIM2 was also observed in tumor tissues isolated from patients with colorectal cancer compared with non-tumor tissues ( Figure S1B ). We treated cohorts of WT and Aim2 -/-mice with AOM followed by DSS and examined the development of colon tumors after 80 days. We found that Aim2 -/-mice developed significantly increased numbers and size of tumors throughout the middle and distal colon compared with WT mice (Figures 1D-1F ). Aim2 -/-mice also tended to lose more body weight over the course of DSS treatment after injection of AOM ( Figure 1G ). Histopathological analysis revealed that Aim2 -/-mice exhibited increased hyperplasia in the proximal, middle, and distal colon ( Figure 1H ). Low-grade dysplasia was restricted to tumorbearing WT mice, whereas both low-and high-grade dysplasia was observed in Aim2 -/-mice ( Figures 1I and 1J ). These results suggested that AIM2 mediated protection against colorectal tumorigenesis.
AIM2 Controls Tumor Development Independently of Inflammasomes AIM2 is a dsDNA receptor that contributes to the host defense against bacterial and viral pathogens by inducing inflammasome responses, including the production of IL-18. We and others have previously shown that IL-18 induced by the related inflammasome, NLRP3 inflammasome, is required for protection against colitis and colitis-associated tumorigenesis (Allen et al., 2010; Zaki et al., 2010a; Zaki et al., 2010b) . To investigate the molecular mechanism underpinning AIM2-dependent protection against colorectal tumorigenesis, we first examined whether there was a lack of inflammasome signaling in Aim2 -/-mice that could be responsible for their increased susceptibility to tumorigenesis. We analyzed the levels of caspase-1 processing in the colon of WT and Aim2 -/-mice and found similar levels of caspase-1 activation 14 days after injection of AOM ( Figure 2A) . We also detected similar levels of IL-18 in the colon tissues and sera of untreated WT and Aim2 -/-mice or in WT and Aim2 -/-mice 8, 14, or 80 days after injection of AOM ( Figure 2B ). To further confirm these results, we measured IL-1b and found similar levels of this inflammasome-dependent cytokine in the colon tissues of untreated WT and Aim2 -/-mice or in WT and Aim2 -/-mice 14 or 80 days after injection of AOM ( Figure 2C ). Although AIM2 functioned independently of the inflammasome in protection against colonic tumorigenesis, we investigated whether other inflammatory mediators might be playing a role in the absence of AIM2 that could have accelerated the progression of colorectal cancer. Shortening of the colon during DSS treatment is a hallmark of inflammation. However, we observed similar colon lengths in WT and Aim2 -/-mice 14 or 80 days after injection of AOM ( Figure 2D ). The NF-kB pathway is a major driver of inflammation. To this end, we analyzed phosphorylation of extracellular signal-regulated kinase (ERK) and IkBa in colon tissues of WT and Aim2 -/-mice following AOM-DSS treatment. Both groups of mice exhibited similar levels of phosphorylated ERK and IkBa ( Figure 2E ). In agreement, the levels of pro-inflammatory cytokines IL-6, tumor-necrosis factor (TNF), and granulocyte colony-stimulating factor (G-CSF) and the chemokine CXCL1 (KC) were not significantly increased in Aim2 -/-mice 14 days after injection of AOM when compared with WT mice ( Figure 2F ). However, an increase in the levels of TNF, G-CSF, and KC was observed 80 days after injection of AOM ( Figure 2F ). We further assessed the levels of cytokines (legend continued on next page) IL-22, IL-23p19, IFN-b, IFN-g, and IL-17A. Using qRT-PCR analysis, we found that the expression of genes encoding these cytokines was similar in colon tissues of untreated WT and Aim2 -/-mice and in colon tissues of WT and Aim2 -/-mice 14 days after injection of AOM ( Figures S2A and S2B) . However, Aim2 -/-mice had an increase in the expression of genes encoding IL-10 14 days after injection of AOM ( Figure S2C ). Furthermore, we found that the expression of genes encoding TGF-b1 and TGF-b2 was similar in colon tissues of untreated WT and Aim2 -/-mice and in WT and Aim2 -/-mice 14 days after injection of AOM ( Figure S2C ). We used an automated hematology analyzer to determine the number and influx of circulating white blood cells from the peripheral blood of WT and Aim2 À/À mice. We observed similar levels of neutrophils, lymphocytes, monocytes, eosinophils, and basophils and total white blood cells in the blood of WT and Aim2 À/À mice 14 or 80 days after injection of AOM ( -/-mice ( Figure 2G ). In addition, the prevalence of splenic and MLN-associated CD11b + cells producing TNF or IL-6 was also similar in WT and Aim2 -/-mice ( Figure 2G ). The prevalence of total CD11b + cells was, however, elevated in the spleen, but not in the MLN. The modest increases in some inflammatory parameters in mice lacking AIM2 suggested a role for an immunological component in shaping tumor development in these mice. Identification of a role for AIM2 independently of classical inflammasome signaling and a number of other inflammatory mediators also suggested, at least in part, alternative functions for AIM2 in the regulation of gastrointestinal homeostasis during colorectal tumorigenesis.
AIM2 Controls Proliferation of Enterocytes
Given that the increased susceptibility to tumor development in Aim2 -/-mice could not be explained by differences in inflammasome activity or by a number of inflammatory mediators, we asked whether AIM2 regulated cellular proliferation or death following exposure to AOM and DSS. We used immunohistochemistry techniques to identify proliferative cells in the colon of WT and Aim2 -/-mice. We observed a significantly higher number of BrdU + proliferative cells per crypt in the colon of Aim2 -/-mice 14, but not 8, days after injection of AOM ( Figure 3A ). We confirmed these findings and found a significantly higher number of Ki67 + cells per crypt in the intestinal epithelium of Aim2 -/-mice 14 days after injection of AOM compared with WT mice, whereas no difference was observed in untreated WT and Aim2 -/-mice ( Figure 3A ). Further, we used microarray analysis to screen for genes expressed differentially in colon tissues of WT and Aim2 -/-mice 14 days after injection of AOM. Using this approach, we indeed identified increased expression of genes encoding molecules involved in cell proliferation in Aim2
-/-mice relative to their expression in WT mice ( Figure 3B ). These included genes encoding S100A9 and BIRC5, which have previously been linked to colorectal carcinoma in humans (Bonte et al., 2008; Vonlanthen et al., 2014; Zhao et al., 2010) . We confirmed, using qRT-PCR analysis, an increased expression of the top three differentially expressed genes encoding molecules involved in proliferation, S100A9, SNRPD1, and DBF4, identified in our microarray ( Figure 3C ). To further investigate the mechanism of unchecked cellular proliferation when AIM2 was absent, we examined activities of the phosphatidylinositol 3-Kinase-AKT pathway, which has a major role in cell proliferation and survival and in development of cancer (Vivanco and Sawyers, 2002) . We found increased phosphorylation of AKT at Ser473 in Aim2 -/-mice compared with WT mice 14 days after injection of AOM ( Figure 3D ), indicating activation of the AKT pathway. Phosphorylation of AKT at Ser473 was similar between WT and Aim2 -/-mice 80 days after injection of AOM ( Figure 3D ). The phosphatidylinositol 3-Kinase-AKT pathway is negatively regulated by the tumor suppressor PTEN (Stambolic et al., 1998) . Phosphorylation of PTEN at S380, T382, and T383 maintains PTEN in a relatively inactive state (Vazquez et al., 2000) . Indeed, we saw increased phosphorylation of PTEN at S380, T382, and T383 in Aim2 -/-mice compared with WT mice 14 days after injection of AOM ( Figure 3D ).
Increased AKT activation and transcription of genes involved in cell proliferation could explain increased proliferation in the colon of mice lacking AIM2 following damage induced by AOM. Consistent with increased AKT activation, we found an elevated level of the transcription factor and proto-oncogene c-Myc in Aim2 -/-mice compared with WT mice 14 and 80 days after injection of AOM ( Figure 3E ). Expression of the transcription factor HIF1-a, however, was similar between WT and Aim2 -/-mice ( Figure 3E ). We further confirmed by qRT-PCR analysis an increased expression of the gene encoding c-Myc ( Figure 3F ). In addition, increased intestinal cell proliferation was linked to reduced apoptosis because the levels of caspase-3 and caspase-7 activation in the colon of Aim2 -/-mice decreased compared with that in WT mice (Figures 3G and 3H) . To examine possible intrinsic defects in the mucus layer in mice lacking AIM2, we analyzed the thickness of the mucus layer and the expression of genes encoding mucin, MUC2, MUC3, and MUC4, in WT and Aim2 -/-mice. We found that the thickness of the mucus layer lining the large intestine and the expression levels of genes encoding MUC2, MUC3 and MUC4 were similar (E) Immunoblot analysis (left) and densitometric quantification of band intensity of phosphorylated and total ERK and IkBa (right) in colon tissues of WT and Aim2 -/-mice 14 days after injection of AOM. (legend continued on next page)
in WT and Aim2 -/-mice ( Figures S3A and S3B ). In addition, we quantified the number of goblet cells and observed similar numbers of these cells in the crypts of WT and Aim2 -/-mice ( Figure S3C ).
AIM2 Controls Expansion of Intestinal Stem Cells
We and others have previously identified intestinal stem cells as the ''cell-of-origin'' of intestinal cancer Zhu et al., 2009) . We hypothesized that the dramatic increase in cell proliferation and tumor formation in Aim2 -/-mice was caused by a population of intestinal stem cells that is susceptible to oncogenic insults. To investigate this, we cultivated and measured the growth rate of stem cells harvested from the colonic epithelia of untreated WT and Aim2 -/-mice. Remarkably, colonic epithelial stem cells harvested from Aim2 -/-mice consistently formed more organoids over 5 days compared with those harvested from WT mice (Figure 4 ). In addition, we measured the diameters of these organoids and found that a greater proportion of organoids originated from Aim2 -/-mice with a larger size compared with those isolated from WT mice (Figure 4 ). These data indicated that stem cells derived from the colon of Aim2 -/-mice exhibited an increased capacity to proliferate.
We and others have previously demonstrated that stem cells or progenitor cells in the small intestine of mice are highly susceptible to tumorigenesis induced by aberrant activating b-catenin mutations (Snippert et al., 2009; Zhu et al., 2009 ). These cells are marked by Prom1 (CD133), a marker of cancer stem cells in human intestinal tumors that arise as a result of aberrant wingless-int (Wnt) signaling (Bienz and Clevers, 2000; Sparks et al., 1998) . To investigate the role of AIM2 in this pathway, we used the Prom1
CreERT2-LacZ (C-L)/+ ; Ctnnb1 lox(ex3)/+ ; RosaZsGreen mouse strain to investigate proliferation of Prom1 + cells following aberrant Wnt signaling (Zhu et al., 2009 AIM2 did not alter Prom1 expression pattern in the large intestine, and the majority of cells in the colonic crypts expressed Prom1 ( Figure S4A ). Remarkably, 3 weeks after induction of aberrant b-catenin activation by tamoxifen treatment, we observed a significant increase in the stem cell activity of Prom1 + cells, indicated by GFP lineage tracing using the (Figure 5B) . These results validated the colitis-associated colorectal cancer model and suggested that AIM2 played a role in protecting tumor formation in the intestine. Overall, loss of AIM2 resulted in an increased stem cell activity in the colon following aberrant Wnt-signaling in the intestinal stem-cell niche.
To further confirm a role for the epithelial compartment in AIM2-mediated protection against colon cancer development, we performed bone marrow transplantation experiments to examine the contribution of the radio-resistant stromal compartment relative to that of the hematopoietic compartment in governing colon tumorigenesis. As expected, Aim2 -/-mice, which received Aim2 -/-bone marrow, were more susceptible to tumorigenesis compared to WT mice, which received WT bone marrow ( Figure 6A ). After 80 days post-AOM injection, Aim2 -/-mice, which received WT bone marrow, had significantly increased tumor burden compared to WT mice, which received WT bone marrow ( Figures 6B and 6C ). These results provided evidence to suggest that AIM2 in the stromal compartment could play a role in the protection against colorectal tumorigenesis. WT mice, which received Aim2 -/-bone marrow also showed slightly increased tumor compared with WT mice, which received WT bone marrow, suggesting that bone marrow compartment contributed to colorectal tumorigenesis via a yet-undefined mechanism.
AIM2 Protects Colorectal Tumorigenesis by Modulating the Gut Microbiota
Intestinal cell proliferation and the development and progression of colorectal cancer is regulated by the composition of gut microbiota. Studies have reported that the NOD-like receptor protein NLRP6 modulates the microbial ecology and protects against colon tumor development (Elinav et al., 2011; Normand et al., 2011) . To assess whether the gut microbiota plays a role in the increased tumorigenic susceptibility of Aim2 -/-mice, we performed 16S rRNA gene sequencing analysis of the gut microbiota derived from stool samples of separately housed WT and Aim2 -/-mice. Our 16S rRNA gene sequencing analyses revealed a markedly distinct intestinal microbial landscape in separately housed WT and Aim2 -/-mice ( Figures 7A and 7B ). Relative to WT mice, Aim2 -/-mice harbored increased levels of Akkermansia muciniphila and Anaeroplasma and decreased levels of Anaerostipes, Bifidobacterium, Flexispira, Prevotella, and Paraprevotella species ( Figure 7A ). Of these, previous reports have linked an increase in Akkermansia and a decrease in Prevotellaceae with the development of colonic tumorigenesis (Zackular et al., 2013) . Interestingly, co-housing equilibrated the relative abundance of Anaerostipes, Flexispira, Prevotella, and Paraprevotella in WT and Aim2 -/-mice ( Figures 7A and 7B ).
We took advantage of the transmissible nature of the gut microbiota to investigate whether susceptibility to colorectal tumorigenesis could be reduced in Aim2 -/-mice by co-housing them with WT mice. Although we observed no major difference in body weight between single-housed or co-housed WT and Aim2 -/-mice during AOM-DSS treatment ( Figure S5 ), we found a striking reduction in the number and incidence of colon tumors in co-housed Aim2 -/-mice compared with separately housed Aim2 -/-mice ( Figures 7C and 7D) . Intriguingly, WT mice cohoused with Aim2 -/-mice responded conversely and developed more tumors compared with their separately housed controls ( Figures 7C and 7D ). Co-housed Aim2 -/-mice were still more susceptible to tumorigenesis compared with co-housed WT mice ( Figures 7C and 7D ), supporting the concept that both genetic and environmental factors contributed to the development of cancer.
DISCUSSION
Members of the pattern-recognition receptor family are central players in the regulation of infectious, inflammatory, and metabolic diseases. Our laboratory and others have previously shown that the innate immune receptors NLRP3, NLRP6, NLRP12, NLRC4, STING, and NOD2 are required for the protection against colitis and colitis-associated tumorigenesis (Allen et al., 2010; Allen et al., 2012; Elinav et al., 2011; Hu et al., 2010; Normand et al., 2011; Watanabe et al., 2008; Zaki et al., 2010a; Zaki et al., 2010b; Zaki et al., 2011; Zhu et al., 2014) . However, the role of AIM2-like receptors, including AIM2 and IFI16 or p202, in regulating gastrointestinal health and disease is unknown. The innate immune receptor AIM2 was originally isolated from human melanoma cells (DeYoung et al., 1997) . AIM2 directly binds dsDNA and initiates the recruitment of ASC and caspase-1 to assemble a multi-protein inflammasome complex. Whether AIM2 can operate independently of inflammasomes in See also Figure S4 .
the cell is unclear. Here, we identified an unexpected function for AIM2 that departs from its known role in inflammasome signaling. Certain members of the NLR family, including NLRP6 and NLRP12, have also been shown to exert inflammasomedependent and inflammasome-independent functions in health and disease . The mechanism driving AIM2-dependent protection against tumorigenesis is the ability of AIM2 to tightly suppress overt cellular proliferation of intestinal epithelial cells. Whether AIM2 directly interacts with and prevents phosphorylation of the kinase AKT is unclear. Unlike the role for NLRP6 in targeting goblet cell mucin secretion (Wlodarska et al., 2014) , AIM2 specifically controlled expansion and proliferation of intestinal stem cells. The larger population of cells derived from Prom1 + cells lining the intestinal crypt in mice lacking AIM2 following aberrant induction of b-catenin indicated that these cells might be highly proliferative and less well differentiated. In vitro studies have shown that ectopic expression of AIM2 can be used to promote cell-cycle arrest and inhibition of cell proliferation (Patsos et al., 2010) . These findings, together, highlight the dynamic roles of AIM2 in regulating cell functions during cell growth and tumorigenesis.
In mice exposed to AOM-DSS, the expression of AIM2 was downregulated as early as 14 days, suggesting that robust AIM2 expression was critical for preventing early tumorigenic events. The levels of AIM2 expression in tumor tissues of patients have been shown to greatly influence the outcome of the disease. Patients who have tumor cells that completely lacked AIM2 expression have a more than 3-fold higher mortality rate than patients whose tumor cells retained some AIM2 expression (Dihlmann et al., 2014) . The precise molecular signal that triggers downregulation of AIM2 expression during colorectal tumorigenesis is unknown, and therapeutic strategies aimed at increasing colonic AIM2 expression may help to prevent overt tumorigenesis in susceptible individuals.
Of particular clinical relevance is the observation that defective AIM2 function leading to tumorigenesis can be partially prevented by a transmissible gut microbiota in cohoused mice. This finding indicates that engraftment of healthy donor gut microbiota to patients suffering chronic intestinal inflammation could reduce the risk of developing colorectal cancer. The microbiota plays a central role in modulating cell proliferation in the intestine. Gut-associated Lactobacillus murinus enhances cell proliferation in the mouse intestine (Okada et al., 2013) . Furthermore, gut microbiota has the capacity to induce IL-17C production in intestinal epithelial cells via a MyD88-dependent pathway, which leads to increased expression of the prosurvival proteins Bcl2 and Bcl-x L to drive colorectal tumorigenesis (Song et al., 2014) . Carbohydrate-derived metabolites generated by gut microbiota have also been shown to enhance colon epithelial cell proliferation in an APC
Min/+ mouse model lacking the gene encoding the DNA mismatch repair protein MutS homolog 2 (MSH2) (Belcheva et al., 2014) . During barrier damage, it is possible that DNA from microbial species that have invaded intestinal cells or DNA from dying host cells could be sensed by AIM2 in intestinal cells. It is tempting to hypothesize that, instead of contributing to inflammatory response further by inducing activation of the inflammasome, AIM2 responds by dampening cellular proliferation in the intestine. How AIM2 might be sensing different environmental cues in the cytoplasm to direct context-specific cellular processes is an exciting question for future investigation. In conclusion, our findings demonstrated a requirement for AIM2 in the protection against colorectal cancer. Therapeutic modulation of AIM2 expression and gut microbiota could play a central role in reducing the risk of developing colorectal cancer. ;Ctnnb1 lox(ex3)/+ mice were described previously (Harada et al., 1999; Jones et al., 2010; Lakhani et al., 2006; Mariathasan et al., 2004; Zhu et al., 2009 
Induction of Tumors
For the AOM and DSS model ( Figure S1A ), mice were injected intraperitoneally with 10 mg of AOM (Sigma) per kg body weight. Five days later, 3% DSS (molecular mass 36-40 kDa; MP Biologicals) was given in the drinking water for 6 days followed by regular drinking water for 2 weeks. This cycle was repeated twice with 2.5% DSS, and mice were sacrificed on day 80. For Day 8 samples, mice were injected with AOM, and after 5 days, they were fed with 3% DSS for 3 days before mice were sacrificed. For day 14 samples, mice were injected with AOM, and after 5 days, they were fed with 3% DSS for 6 days.
Mice were then fed with regular water for 3 days and sacrificed. For co-housing experiments, equal numbers of female WT and female Aim2 -/-mice were housed in the same cage for 4 weeks. Mice were then housed separately prior to AOM injection and remained separated over the course of the experiment. To induce aberrant Wnt signaling, tamoxifen induction was performed on 2-month-old mice by oral gavage with 200 ml tamoxifen (20 mg/ml) in corn oil for 2 days.
Histology and Microscopy Analysis
Colon tissues were fixed in 10% formalin, embedded in paraffin, sectioned, and stained with H&E. The number of proliferating cells in the intestinal epithelium was detected by immunoperoxidase staining for thymidine analog 5 0 -bromo-2 0 deoxyuridine (BrdU) as described previously (Rakoff-Nahoum et al., 2004) . In brief, 1 mg/ml BrdU in PBS was injected intraperitoneally. Colon tissues were collected after 2 hr and fixed in 10% neutral buffered formalin and embedded in paraffin. Immunohistochemistry was performed using the in situ BrdU staining kit according to manufacturer's instructions (BD Bioscience, 550803). Ki67 (NBP1-40684, Novus), AKT (4691, Cell Signaling), p-AKT (Ser473; 4060, Cell Signaling), and c-Myc (5605, Cell Signaling) staining were performed using antibodies according to the manufacturers' instructions. Tissues were counterstained with hematoxylin. The number of Ki67-or BrdU-positive cells per crypt in each animal was counted (at least 18-20 crypts per mouse). To visualize goblet cells, colon tissues were stained with PAS and Alcian blue. The number of goblet cells per crypt was enumerated. For nLacZ analysis and GFP microscopy, tissues were perfused and fixed in 2% paraformaldehyde overnight, cryo-protected, and frozen in OCT. Sections were stained for b-galactosidase or examined for GFP signal. For b-galactosidase staining, frozen sections were washed in PBS for 5 min and incubated in the dark in standard b-galactosidase substrate (5 mM potassium ferricyanide, 5 mM potassium ferrocyanide, 1 mg/ml X-gal, 2 mM MgCl 2 , 0.01% sodium deoxycholate, and 0.02% NP-40 in PBS) for 4 hr at 37 C. Sections were then rinsed and counterstained by Nuclear Fast Red (Vector, H-3403).
Real-Time qRT-PCR RNA was isolated using Trizol and converted into cDNA. Gene expression was assessed using 2 3 Sybrgreen kit according to the manufacturer's instructions (Applied Biosystems). Sequences for qRT-PCR primers are listed in Table S1 .
The cancer survey cDNA array was used to evaluate human AIM2 gene expression in tumor tissues, which was performed according to the manufacturer's instructions (Origene).
Cytokine Measurement
Cytokines in colon and sera were measured by ELISA according to manufacturers' instructions. The IL-18 ELISA was from eBioscience. Multiplex ELISAs were used for all other cytokines (Millipore).
Western Blotting
Proteins were extracted from colon tissues using RIPA lysis buffer supplemented proteinase and phosphatase inhibitors (Roche). Samples were resolved in 12%-15% SDS-PAGE and transferred onto PVDF membranes. Blocking was performed in 5% milk for 1 hr, and membranes were incubated in primary antibodies overnight at 4 C. Membranes were incubated with HRPconjugated secondary antibody for 1 hr, and proteins were visualized using ECL substrate (ThermoScientific). The primary antibodies were caspase-1 p10 (1:500 dilution, sc-515, Santa Cruz), p-ERK 
Colon Organoid Culture
Mouse colon stem cells were cultured as previously described with modifications (Yui et al., 2012) . Briefly, mice were perfused with prewarmed 30 mM EDTA in PBS. Colon was removed and rinsed with PBS. Colonic mucosa was scraped from the muscle layer and kept in 10 mM EDTA in PBS on ice and incubated in a shaker at 350 RPM for 15 min at 4 C. Dissociated colonic crypts were vigorously suspended. Cells were filtered through a 70 mm cell strainer, mixed with Matrigel (BD Bioscience, 354230) and plated in 60 mm plates. The culture medium consisted of Advanced DMEM/F12 supplemented with B27, N2, N-Acetylcysteine, Gastrin (10 nM), and growth factors, including 50 ng/ml EGF, 1 mg/ml R-spondin1, 100 ng/ml Noggin, 100 ng/ml FGF10, and Wnt3A conditioned media (Willert et al., 2003) .
Bone Marrow Chimeras
Mice were subjected to split-dose irradiation, first with a 350 rad dose, followed by a 950 rad dose 24 hr later. 2 hr after the second dose of irradiation, mice were injected intravenously with 10 7 bone marrow cells from the femur and tibia of donor mice. The following four groups of chimeric mice were generated: WT / WT (CD45. 
Aim2
À/À cells into CD45.2-expressing Aim2 À/À mice). The reconstitution rate evaluated 6 weeks after bone marrow transfer was determined by flow staining of CD45.1 and CD45.2 in blood leukocytes, which was at least 95%.
Universal Sequencing of the Gut Microbiota Genomic DNA from feces were extracted by QiAMP DNA stool Mini Kit (QIAGEN) and used for 16S rRNA gene sequencing. Libraries were prepared by amplification of the 16S v4 domain according to the manufacturer's instructions (Bioo Scientific Corporation). Paired-end 150 cycle sequencing was performed on a MiSeq using 300 cycle v2 sequencing kits according the manufacturer's instructions (Illumina) with the following modifications: a phiX library was spiked in at$10%, and library specific sequencing primers were added to the Illumina primer wells as specified by the manufacturer (Bioo Scientific Corporation).
Statistical Analysis
Statistical significance was determined by Student's t test or ANOVA; p < 0.05 was considered statistically significant where *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is GEO: GSE69436. The study number for the microbiota sequences reported in this paper is NCBI: SRP059020. 
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